Taken together, the figure highlights a key mechanistic principle underlying the therapeutic rationale for multi-agonist strategies: while GLP-1R monotherapy achieves meaningful metabolic and hepatic benefits exclusively through indirect, systemic pathways, the addition of GIPR and - most importantly - GCGR co-agonism introduces complementary and increasingly direct hepatic mechanisms, providing the pharmacological basis for the superior efficacy observed with dual and triple agonists in MASLD/MASH
Write down questions to ask your doctor
#BELLENUBIAN Maintain a healthy-looking, radiant complexion through every season.
By the mid-1980s, the amino acid sequence for GLP-1 was discovered
CHRIS MASTERJOHN: Heart is the best
Standard GLP-1 side effects (nausea, constipation, occasional pancreatitis, gallbladder issues) apply equally